Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 00:42 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC.
NCT03968419 · Novartis Pharmaceuticals · PHASE2 · terminated · last registry update 2024-06-20 · Non-small cell lung cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Study early terminated due to low enrollment compared to the anticipated figures.” | Open Targets' class: insufficient enrollment | Registry record, Novartis Pharmaceuticals |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IL1B in non-small cell lung cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-10-09Also stopped (terminated): Novartis Pharmaceuticals, Canakinumab + Placebo (NCT03447769)
- 2024-10-08Results posted on the registry: Novartis Pharmaceuticals, canakinumab + canakinumab-matching placebo (NCT03631199)
- 2024-01-30Results posted on the registry: Novartis Pharmaceuticals, Canakinumab + Placebo (NCT03447769)
- 2023-08-21Also stopped (terminated): Novartis Pharmaceuticals, Canakinumab + Docetaxel (NCT03626545)
- 2023-06-22Results posted on the registry: Novartis Pharmaceuticals, Canakinumab + Docetaxel (NCT03626545)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision